RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q1 FY20 results · Apr–Jun 2019
RPG Life Sciences reported revenue from operations of ₹94.04 crore (up 17.7% from Q1 FY19) and net profit of ₹8.35 crore (up 356.3% from Q1 FY19) for Q1 FY20 (Apr–Jun 2019), on a standalone basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 94.04 | 79.89 | +17.7% | 68.80 | +36.7% |
| Other income | 0.16 | 0.39 | −59.0% | 0.42 | −61.9% |
| Total income | 94.20 | 80.28 | +17.3% | 69.22 | +36.1% |
| Profit before tax | 10.86 | 2.58 | +320.9% | 2.12 | +412.3% |
| Net profit for the period | 8.35 | 1.83 | +356.3% | 1.54 | +442.2% |
| EPS, basic (₹) | 5.05 | 1.11 | +355.0% | 0.93 | +443.0% |
| Net margin (%) | 8.9 | 2.3 | 2.2 |
Standalone
- Filed with BSE
- 31 Jul 2019, 14:11 IST
- Board meeting
- 30 Jul 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE